VA NEPHRON-D: Diabetes iN Nephropathy Study
Public ClinicalTrials.gov record NCT00555217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Diabetes is the leading cause of end-stage renal disease (ESRD) in the United States. The overall rate of ESRD secondary to diabetes has risen 68% since 1992. Medications that block the renin angiotensin system have been shown to decrease the progression of diabetic nephropathy. The use of an angiotensin receptor blocker (ARB) has been shown to decrease the risk of progression of kidney disease in two studies of individuals with Type 2 diabetes and proteinuria. Despite the use of an ARB, the incidence of renal failure remained high in the treated group in both studies. The combination of an angiotensin converting enzyme inhibitor (ACEI) and ARB can lead to more complete blockade of the renin angiotensin system. In diabetic kidney disease, combination therapy has been shown to decrease proteinuria in short-term studies. Although there are encouraging results for improvement in proteinuria there are no data on progression of kidney disease for the use of combination of ACEI and ARB therapy in patients with diabetes. In addition, there could be an increased risk of serious hyperkalemia in individuals with diabetes who receive combination ACEI and ARB. The investigators therefore propose a randomized double blind multi-center clinical trial to assess the effect of combination of ACEI and ARB in patients with diabetes and proteinuria on progression of kidney disease.
Study identification
- NCT ID
- NCT00555217
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,448 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Sep 2014 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- May 29, 2015
2008 – 2014
United States locations
- U.S. sites
- 30
- U.S. states
- 24
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Carl T. Hayden VA Medical Center | Phoenix | Arizona | 85012 | — |
| Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock | Little Rock | Arkansas | 72205-5484 | — |
| VA Medical Center, Loma Linda | Loma Linda | California | 92357 | — |
| VA Palo Alto Health Care System | Palo Alto | California | 94304-1290 | — |
| VA Connecticut Health Care System (West Haven) | West Haven | Connecticut | 06516 | — |
| North Florida/South Georgia Veterans Health System | Gainesville | Florida | 32608 | — |
| VA Medical Center, Miami | Miami | Florida | 33125 | — |
| James A. Haley Veterans Hospital, Tampa | Tampa | Florida | 33612 | — |
| Edward Hines, Jr. VA Hospital | Hines | Illinois | 60141-5000 | — |
| Richard Roudebush VA Medical Center, Indianapolis | Indianapolis | Indiana | 46202-2884 | — |
| VA Medical Center, Iowa City | Iowa City | Iowa | 52246-2208 | — |
| VA Maryland Health Care System, Baltimore | Baltimore | Maryland | 21201 | — |
| VA Medical Center, Minneapolis | Minneapolis | Minnesota | 55417 | — |
| VA Medical Center, Kansas City MO | Kansas City | Missouri | 64128 | — |
| VA Medical Center, St Louis | St Louis | Missouri | 63106 | — |
| VA Medical Center, Omaha | Omaha | Nebraska | 68105-1873 | — |
| VA New Jersey Health Care System, East Orange | East Orange | New Jersey | 07018 | — |
| New Mexico VA Health Care System, Albuquerque | Albuquerque | New Mexico | 87108-5153 | — |
| VA Western New York Healthcare System at Buffalo | Buffalo | New York | 14215 | — |
| VA Medical Center, Durham | Durham | North Carolina | 27705 | — |
| VA Medical Center, Cleveland | Cleveland | Ohio | 44106 | — |
| VA Medical Center, Portland | Portland | Oregon | 97201 | — |
| VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA | Pittsburgh | Pennsylvania | 15240 | — |
| Ralph H Johnson VA Medical Center, Charleston | Charleston | South Carolina | 29401-5799 | — |
| WJB Dorn Veterans Hospital, Columbia | Columbia | South Carolina | 29209 | — |
| VA Medical Center, Memphis | Memphis | Tennessee | 38104 | — |
| VA Medical Center | Nashville | Tennessee | 37212-2637 | — |
| VA North Texas Health Care System, Dallas | Dallas | Texas | 75216 | — |
| Hunter Holmes McGuire VA Medical Center | Richmond | Virginia | 23249 | — |
| Zablocki VA Medical Center, Milwaukee | Milwaukee | Wisconsin | 53295-1000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00555217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2015 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00555217 live on ClinicalTrials.gov.